Table 5 Extent of mono- and combination drug therapy use in the female LUTS (including OAB) sub-cohort
Monotherapy | N | % of monotherapy patients | % of all patients in female OAB sub-cohort | % of all female patients |
|---|---|---|---|---|
Any OAB drug monotherapy | 26,338 | 100.0 | 90.5 | 85.6 |
Any antimuscarinic monotherapy | 24,263 | 92.1 | 83.4 | 78.8 |
Solifenacin | 10,083 | 38.3 | 34.7 | 32.8 |
Oxybutynin | 7852 | 29.8 | 27.0 | 25.5 |
Tolterodine | 4020 | 15.3 | 13.8 | 13.1 |
Mirabegron | 2075 | 7.9 | 7.1 | 6.7 |
Fesoterodine | 1173 | 4.5 | 4.0 | 3.8 |
Trospium | 754 | 2.9 | 2.6 | 2.4 |
Darifenacin | 209 | 0.8 | 0.7 | 0.7 |
Flavoxate | 96 | 0.4 | 0.3 | 0.3 |
Propiverine | 76 | 0.3 | 0.3 | 0.2 |
Combination drug therapy | N | % of combination drug therapy patients | % of all patients in female OAB sub-cohort | % of all female patients |
|---|---|---|---|---|
All combination drug therapy | 2756 | 100.0 | 9.5 | 9.0 |
Any ≥ 2 OAB drugs | 2621 | 95.1 | 9.0 | 8.5 |
Mirabegron + any antimuscarinic | 788 | 28.6 | 2.7 | 2.6 |
Any ≥ 2 antimuscarinics (± mirabegron) | 1847 | 67.0 | 6.3 | 6.0 |
Duloxetine + any OAB drug | 144 | 5.2 | 0.5 | 0.5 |
Solifenacin + tolterodine | 507 | 18.4 | 1.7 | 1.6 |
Oxybutynin + solifenacin | 458 | 16.6 | 1.6 | 1.5 |
Mirabegron + solifenacin | 417 | 15.1 | 1.4 | 1.4 |
Fesoterodine + solifenacin | 174 | 6.3 | 0.6 | 0.6 |
Oxybutynin + tolterodine | 174 | 6.3 | 0.6 | 0.6 |
Other combinations | 1026 | 37.2 | 3.5 | 3.3 |
Drug class | N | % of all patient in OAB sub-cohort | % of all female patients |
|---|---|---|---|
Any OAB drug | 29,094 | 100 | 94.5 |
Any antimuscarinic | 27,010 | 92.8 | 87.7 |
Total mirabegron | 2972 | 10.2 | 9.7 |